MEDCAPTAIN
| Register Close | 2026/09/02 IPO Closing in 5 Days |
| Listing Date | 2026/09/07 |
| Register Close | 2026/09/02 IPO Closing in 5 Days |
| Listing Date | 2026/09/07 |
Medcaptain Medical Technology Co., Ltd.is a global medical device provider, serving clinical needs across a wide range of clinical departments, wards and offices within medical institutions, as well as community health centers, testing facilities and home care scenarios.
--
The Group medical products are distributed across the APAC, EMEA and AMER regions. It strategically positioned five R&D centers and six manufacturing centers across China and the UK. It provides reliable sales and after-sales support across multiple time zones.
--
As of March 31, 2026, the Group’s product portfolio included over 60 life support products, 110 minimally invasive intervention products, and 150 in vitro diagnostics products. Its products have cumulatively reached over 140 countries and regions globally. In China, its products have cumulatively reached over 6,000 hospitals, including approximately 90% of Grade 3A hospitals, covering all 31 provinces, municipalities and autonomous regions.
--
Life support medical devices are predominantly utilized in the ICUs, operating rooms and emergency rooms for the management and care of critically ill patients. including medication delivery products, anesthesia machines and vaporizers, and other life support products such as airway management, pulmonary function testing devices, deep vein thrombosis, or DVT, preventive pumps, vein illuminators, monitors, and veterinary life support products. Its minimally invasive intervention products are primarily used in the diagnosis and treatment of conditions relating to the digestive system, including the gastrointestinal and hepatobiliary tracts, and the urological system.
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | Global |
| Board Lot | 100 |
| No. of Offer Shares | 38.91M H shares |
| No. of International Offer Shares | 35.02M H shares |
| No. of HK Offer Shares | 3.89M H shares |
| Offer Price | $15.42 |
| Stock Code | 2041 |
| Sponsor(s) | Morgan Stanley Asia Limited, Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, Huatai Financial Holdings (Hong Kong) Limited, BNP Paribas Securities (Asia) Limited, Celestial Securities Limited, Eddid Securities and Futures Limited, Futu Securities International (Hong Kong) Limited, Huafu International Securities Limited, Jinluo Securities Limited, SBI China Capital Financial Services Limited, TradeGo Markets Limited, UOB Kay Hian (Hong Kong) Limited, Yuet Sheung International Securities Limited |
| Application Period | Aug 28 (Fri) - noon, Sep 02 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Sep 04 (Fri) |
| Result Announcement Date | On or before Sep 04 (Fri) |
| Result Announcement Date | On or before Sep 07 (Mon) |
| Dealings in Shares commence on | Sep 07, 2026. (Mon) |
| Offer Price | $15.42 |
| Capitalization (H Shares) | 8.31B |
| NAV / share ($) | $2.01 (Unaudited pro forma adj NAV / share) |
| Assuming the offer price being at HKD 15.42, the net proceeds raised would be HKD 496.20M, of which |
| 35% : Ongoing and planned R&D to further enrich product lines to build a competitive portfolio |
| 20% : Develop manufacturing centers to expand our production capacity, including investments in production facilities and upgrades of production lines |
| 20% : Enhance sales and marketing capabilities to support scalable business growth |
| 10% : Potential strategic investments and acquisitions |
| 5% : Upgrade IT infrastructure and digital platform |
| 10% : Working capital |
| Prospectus |
| Remark: | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |